Ayahuasca Ceremonies: What to Expect, What to Question and What Not to Romanticize

Updated September 2026. This article is educational and is not medical or legal advice. Ayahuasca ceremonies range from Indigenous and religious traditions to expensive international retreats with branding decks. Treating all of them as the same thing is culturally lazy and a safety problem. Start with the boring facts Ayahuasca commonly combines DMT-containing plants with beta-carboline MAO inhibitors, which creates…

Read the full article →

Psychedelic-Assisted Therapy for PTSD: Where the Evidence Stands

Updated September 2026. This article is educational and is not medical or legal advice. Here is the useful version, without the incense-cloud certainty: PTSD is one of the most visible targets in psychedelic medicine, especially because of MDMA-assisted therapy research and emerging psilocybin studies. The evidence is promising, regulatory status remains unsettled, and “psychedelic therapy” is not one interchangeable treatment.…

Read the full article →

Long-Term Effects of Psychedelic Use: What Lasts After the Trip

Updated September 2026. This article is educational and is not medical or legal advice. This topic attracts two kinds of writing: breathless evangelism and joyless debunking. Both are lazy. Most psychedelic effects end within hours, but people can report lasting changes in mood, beliefs, behavior and perception. “Lasting” can mean beneficial, neutral or unwanted, and the internet has a bad…

Read the full article →

Microdosing Harm Reduction: What “Safe” Can and Cannot Mean

Updated September 2026. This article is educational and is not medical or legal advice. “Micro” describes an intention to use a low amount; it does not mean risk disappears. Research on repeated low-dose psychedelic use is still limited, products are not standardized in unregulated settings, and interactions or psychiatric vulnerability do not care about branding. What makes the situation riskier…

Read the full article →

Psilocybin Therapy for Depression: Where the Evidence Stands in 2026

Updated September 2026. This article is educational and is not medical or legal advice. Here is the useful version, without the incense-cloud certainty: Psilocybin-assisted therapy for depression now has multiple controlled trials and increasingly serious follow-up data. That is real progress. It still does not make psilocybin a universal antidepressant, erase trial limitations or substitute for individualized medical care. What…

Read the full article →

Psychedelic Art and Its Cultural Impact: From Concert Posters to Algorithmic Surrealism

The subject is stranger than the headline and usually less magical than the marketing. Psychedelic art escaped the 1960s almost immediately. Its distorted type, impossible color, biological geometry and cosmic symbolism migrated into album sleeves, fashion, advertising, animation, rave flyers, digital art and now AI-generated visual culture. Where irony and sincerity meet San Francisco concert posters fused Art Nouveau curves…

Read the full article →

Psychedelic Laws in the United States: Federal Rules, State Experiments and the Mess in Between

Updated September 2026. This article is educational and is not medical or legal advice. This topic attracts two kinds of writing: breathless evangelism and joyless debunking. Both are lazy. American psychedelic law is a layer cake baked by people who apparently hate simple answers. Federal scheduling, state programs, personal-use reforms, local decriminalization, clinical trials and religious exemptions all operate differently.…

Read the full article →

Psychedelics and Dementia: Interesting Hypotheses, Very Early Evidence

Updated September 2026. This article is educational and is not medical or legal advice. Psychedelics are being discussed around dementia because neuroplasticity, depression, apathy and quality of life are real problems. That conversation is scientifically interesting and clinically premature. There is no established psychedelic treatment for Alzheimer’s disease or dementia. Risk, screening and context Most therapeutic psychedelic evidence comes from…

Read the full article →

MDMA-Assisted Therapy in 2026: Promising Data, Regulatory Friction, No Victory Lap Yet

Updated September 2026. This article is educational and is not medical or legal advice. The subject is stranger than the headline and usually less magical than the marketing. MDMA-assisted therapy for PTSD produced striking trial results, then ran directly into the less psychedelic world of trial design, safety reporting and regulatory review. As of September 2026 it is not FDA-approved…

Read the full article →

100 Famous People and Psychedelics: Who Actually Said What?

100 Famous People and Psychedelics: Who Actually Said What?

Here is the useful version, without the incense-cloud certainty: Celebrity psychedelic lists are catnip for the internet and a graveyard for sourcing. This version treats fame as a research problem: public statements, documented writing or credible reporting count; vibes, memes and “my cousin heard” do not. Why the symbol refuses to die Some figures openly described psychedelic use in books,…

Read the full article →